Preface – Part II

Chia-Chi (Josh) Lin, MD, PhD, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan

Chia-Chi (Josh) Lin, MD, PhD,
National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan

Dear Colleagues

Due to the innovations in the field of oncological treatment that have profoundly changed our perception of modern cancer therapy, the design of clinical trials had to be modified appropriately with the purpose of allowing for the assessment of the distinct effects of new drugs. This means that long-standing paradigms had to be abandoned, and new principles took their place. In light of continuing research, which happens at breathtaking speed, this process is still ongoing.

As the size and complexity of phase I trials have been increasing over time, investigators are facing considerable challenges these days. On the other hand, the investigational process can be shortened significantly if patient selection and assessment of treatment efficacy are conducted from the very beginning. Phase II studies used to provide initial assessment of efficacy, but adaptive trial designs in the setting of targeted therapy often lead to amalgamation of phases I and II.

Endpoints play a major role in the design of clinical studies and should therefore be selected carefully. The use of quality-of-life assessments adds valuable information to the data delineating the strengths and weaknesses of a certain treatment.

Given the recent developments, the articles presented in this paper are aimed at updating the reader on aspects of the contemporary designs of phase I and II trials, with an emphasis on endpoint selection and the use of quality of life as a trial outcome. We hope to provide useful information that might contribute to supporting scientific efforts on our way towards finding a cure for cancer.

Author: Chia-Chi (Josh) Lin, MD, PhD, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan

© 2017 Springer-Verlag GmbH, Impressum

More posts

An update and future directions in advanced gastric or gastrointestinal junction cancer (G/GEJC)

With more than 1 million newly diagnosed cases in 2020, gastric cancer (GC) is the fifth most frequent cancer; it was also the third leading cause of cancer-related death worldwide. Gastroesophageal junction (GEJ) cancer concerns a form of gastric cancer developing around the digestive tract where esophagus and stomach connect; in the last years, the prevalence of GEJ constantly increased.

Innovative combinations in esophageal squamous cell carcinoma

Each year, esophageal cancer (EC) is responsible for more than half a million deaths worldwide. Among them, esophageal squamous cell carcinoma (ESCC) accounts for the vast majority (~ 85 %) of EC incidences . At diagnosis, 70 % of ESCC is unresectable [3] and the 5-year survival rate is limited (30 % - 40 %). Patients with advanced or metastatic ESCC have a poor prognosis; their overall survival (OS) after standard first-line chemotherapy is limited to less than a year and other treatment options are scarce.

Novel agents or combinations in recurrent or metastatic nasopharyngeal cancer

Nasopharyngeal cancer (NPC) is a rare malignancy with an incidence of approximately 133,000 annually worldwide, resulting in about 80,000 deaths per year. Whereas early-stage and locally advanced NPC have a good prognosis, treatment of recurrent or metastatic nasopharyngeal cancer is a challenging; it is thus associated with a poor prognosis, especially in patients who have failed two or more lines of systemic therapy, with a median progression-free survival (mPFS) of seven months and median overall survival (mOS) of 22 months.

Preface ASCO Solid Tumor 2022

After 2 years of the COVID-19 pandemic, the Annual Meeting of the American Society of Clinical Oncology (ASCO), was held in Chicago, USA, and virtually from 3rd–7th June 2022.As always, the very much-anticipated event brought leading experts from across the globe together to learn and discuss the groundbreaking updates and scientific advancements which were covered in more than 2,000 abstracts, along with 85 live­stream sessions, and more than 2,500 poster presentations.